Xilio Therapeutics, Inc. Repayments of Debt
Xilio Therapeutics, Inc. (XLO) reported Repayments of Debt of $3.33 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2026-03-23
- Xilio Therapeutics, Inc. repayments of debt for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Xilio Therapeutics, Inc. repayments of debt for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Xilio Therapeutics, Inc. repayments of debt for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Xilio Therapeutics, Inc. repayments of debt for the quarter ending 2024-03-31 was $3.33M, a 99.94% increase year-over-year.
- Xilio Therapeutics, Inc. repayments of debt for fiscal 2024 was $3.33M, a 50.01% decline from fiscal 2023.
- Xilio Therapeutics, Inc. repayments of debt for fiscal 2023 was $6.67M.
- Xilio Therapeutics, Inc. repayments of debt for fiscal 2021 was $1.00M.
| Period end | Repayments of Debt 3 month | Repayments of Debt 6 month | Repayments of Debt 9 month | Repayments of Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $3.33M 10-K · filed 2026-03-23 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $3.33M 10-Q · filed 2025-11-13 | $5.00M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $3.33M 10-Q · filed 2025-08-14 | $5.00M derived: sum of 3 quarters · filed 2025-08-14 | $7.22M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $3.33M 10-Q · filed 2025-05-08 | $5.00M derived: sum of 2 quarters · filed 2025-05-08 | $7.22M derived: sum of 3 quarters · filed 2025-05-08 | $8.33M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $3.89M derived: sum of 2 quarters · filed 2025-03-11 | $5.00M derived: sum of 3 quarters · filed 2025-03-11 | $6.67M 10-K · filed 2025-03-11 |
| 2023-09-30 | $2.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.33M derived: sum of 2 quarters · filed 2024-11-07 | $5.00M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.78M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $1.67M 10-Q · filed 2024-05-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $667.00K derived: sum of 2 quarters · filed 2023-03-02 | $1.00M 10-K · filed 2023-03-02 | |
| 2021-09-30 | $667.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.00M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $333.00K 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |